Oncology │ KRAS

Unlock KRAS G12C for lung cancer treatment decisions

KRAS G12C – the key to a new treatment option

In Europe, lung cancer is the second commonest cancer in males and third commonest in females with >477,500 new cases in 2020 (1). Non-small cell lung cancer (NSCLC) accounts for between 80 and 90% of these cases (2). The specific mutation KRAS G12C is present in 13–15% of NSCLC cases (3, 4) and, until recently, there has been no targeted treatment for KRAS G12C-positive NSCLC, despite decades of research.

The therascreen KRAS RGQ PCR Kit is a clinically validated in vitro diagnostic (IVD) test to identify NSCLC patients that may be eligible for the new treatment LUMYKRAS (sotorasib) based on the detection of the KRAS G12C mutation.

Reliably detect the KRAS mutation that matters

The therascreen KRAS RGQ PCR Kit is a unique molecular test, based on the detection of specific KRAS mutations in tumor DNA isolated from formalin-fixed paraffin-embedded (FFPE) NSCLC tumor tissue. The kit targets seven mutations in codons 12 and 13 of the KRAS gene (G12A, G12D, G12R, G12C, G12S, G12V and G13D).

Get the details

Making precision healthcare possible

We understand that you need to access relevant genomic information for every patient. Our therascreen kits cover a wide range of solid tumors, so that you can make the best treatment decisions possible.

Browse our products

Get the latest insights from oncology experts

Catch up with our solid tumor webinars wherever you are, at a time that works for you.

Go to hub

A woman in protective goggles holding a tablet in a lab

References
1. GLOBOCAN 2020. http://gco.iarc.fr/today. Accessed: January 17, 2022.
2. ESMO. Non-Small Cell Lung Cancer. ESMO Patient Guide Series. esmo.org. Accessed: January 17, 2022
3. Biernacka, A., et al. (2016) Cancer Genetics. S2210-7762, 30021.
4. Sebastian, M., et al. (2021) Lung Cancer. 154, 51.

The therascreen KRAS RGQ PCR Kit is intended for in vitro diagnostic use.